Psychological Impact of the Neurofibromatoses

  • Rosalie E. Ferner


Neurofibromatosis 1 and 2 are inherited tumor suppressor conditions that cause lifelong medical problems and carry a large psychological burden. Anxiety and depression are common but unwelcome bedfellows. The formation of specialist neurofibromatosis clinics has highlighted the value of long-term psychological support both within the clinic setting and in the community for people with NF1 and NF2 and their families. Moreover, the advent of clinical therapeutic trials has focused attention on developing objective measurements of quality of life that are comparable in different medical institutions.


Cochlear Implant Vestibular Schwannomas Plexiform Neurofibroma Cosmetic Problem Optic Glioma 


  1. 1.
    Calm KC. Quality of life in cancer patients: an hypothesis. J Med Ethics. 1984;10:124-127.CrossRefGoogle Scholar
  2. 2.
    Clayton M. Leonardo da Vinci: The Divine and the Grotesque. London: Royal Collection Enterprises; 2002.Google Scholar
  3. 3.
    Lantieri L, Meningaud JP, Grimbert P, et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet. 2008;372:639-645.PubMedCrossRefGoogle Scholar
  4. 4.
    Wolkenstein P, Zeller J, Revuz J, et al. Quality of life impairment in neurofibromatosis 1. Arch Dermatol. 2001;137:1421-1425.PubMedGoogle Scholar
  5. 5.
    Garratt AM, Ruta DA, Abdalla MI, et al. SF36 health survey questionnaire: An outcome measure suitable for routine use within the NHS? Br Med J. 1993;306:1440-1444.CrossRefGoogle Scholar
  6. 6.
    Neary WJ, Hillier VF, Flute T, et al. The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol. 2010;35:291-299.PubMedCrossRefGoogle Scholar
  7. 7.
    Patel C, Ferner R, Grunfeld E. A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med. 2011;16:19-28.PubMedCrossRefGoogle Scholar
  8. 8.
    Plotkin SR, Stemmer-Rachamimov AO, Barker FG. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358-367.PubMedCrossRefGoogle Scholar
  9. 9.
    Neary WJ, Hillier VF, Flute T, et al. Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. J Laryngol Otol. 2010;124:720-728.PubMedCrossRefGoogle Scholar
  10. 10.
    Lusitg LR, Yeagle J, Driscoll CL, et al. Cochlear implantation in patients with neurofibromatosis type 2 and bilateral vestibular schwannoma. Otol Neurotol. 2006;27:512-518.CrossRefGoogle Scholar
  11. 11.
    Kanowitz SJ, Sahpiro WH, Golfinos JG, et al. Auditory brainstem implantation in patients with neurofibromatosis type 2. Laryngoscope. 2004;114:2135-2146.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Rosalie E. Ferner
    • 1
    • 2
  1. 1.Department of NeurologyGuy’s and St. Thomas’ NHS Foundation TrustLondonUK
  2. 2.Department of Clinical Neuroscience, Institute of PsychiatryKing’s CollegeLondonUK

Personalised recommendations